US4333941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of enveloped viruses with phenyl ketones
Assignee: Dow Chemical Co
•
Filing: 1977-10-03
•
Granted: 1982-06-08
•
Expires: 1997-10-03
Abstract
Abstract Enveloped viruses such as rhabdoviruses, herpes viruses, influenza viruses, α viruses and paramyxo viruses are inactivated by contacting the viruses or virus infected cells with a β-aminophenylketone compound such as 4-n-butoxy-β-(1-piperidyl)propiophenone hydrochloride; 3,4-dichloro-β-(1-piperidyl)propiophenone; 4-n-decyloxy-β-(1-piperidyl)propiophenone; or 4-n-butoxy-β-(N,N-diethylamino)propiophenone.
Inventors
- 👤 Brenda S. Baratz
- 👤 Robert A. Phillips
- 👤 David L. Steward
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 15:17
CPC Classifications
C; C12; C12N; C12N7/00; A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16661; C12N2710/16663; C12N2760/00; C12N2760/00011; C12N2760/16011; C12N2760/16034
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
131 words
A method for inhibiting enveloped viruses on non-living substrates which comprises contacting an enveloped virus and a non-living substrate contaminated therewith, with an effective virus inhibiting amount of a phenylketone compound or pharmacologically-acceptable salt thereof, said phenylketone compound corresponding to one of the formulae: ##STR4## wherein R represents hydrogen, halo, or alkoxy of from one to twelve carbon atoms, R' represents hydrogen or halo; R 1 and R 2 represent loweralkyl, or R 1 and R 2 taken together with the nitrogen atom represent a heterocyclic amino group or an N-alkyl quaternary heterocyclic ammonium group having four, five or six carbon atoms and zero or one additional ring hetero atom selected from oxygen, sulfur and nitrogen or R 1 and R 2 , taken together with the nitrogen atom represent triloweralkylammonium.
Claim 2
Independent Claim
131 words
A method for inhibiting enveloped viruses on non-living substrates which comprises contacting an enveloped virus and a non-living substrate contaminated therewith, with an effective virus inhibiting amount of a phenylketone compound or pharmacologically-acceptable salt thereof, said phenylketone compound corresponding to one of the formulae: ##STR4## wherein R represents hydrogen, halo, or alkoxy of from one to twelve carbon atoms, R' represents hydrogen or halo; R 1 and R 2 represent loweralkyl, or R 1 and R 2 taken together with the nitrogen atom represent a heterocyclic amino group or an N-alkyl quaternary heterocyclic ammonium group having four, five or six carbon atoms and zero or one additional ring hetero atom selected from oxygen, sulfur and nitrogen or R 1 and R 2 , taken together with the nitrogen atom represent triloweralkylammonium.
Claim 3
Dependent Claim
11 words
Method of claim 1 wherein the virus is a herpes virus.
Claim 4
Dependent Claim
13 words
Method of claim 1 wherein the virus is herpes simplex virus type 1.
Claim 5
Dependent Claim
13 words
Method of claim 1 wherein the virus is herpes simplex virus type 2.
Claim 6
Dependent Claim
10 words
Method of claim 1 wherein the virus is influenza virus.
Claim 7
Dependent Claim
18 words
Method of claim 1 wherein R 1 and R 2 taken together with the nitrogen atom represent piperidino.
Claim 8
Dependent Claim
33 words
Method of claim 1 wherein the phenylketone compound corresponds to formula I, R' is hydrogen, R is alkoxy and R 1 and R 2 , taken together with the nitrogen atom represent piperidino.
Claim 9
Dependent Claim
10 words
Method of claim 7 wherein the compound is dyclonine hydrochloride.
Claim 10
Independent Claim
155 words
A method for inhibiting enveloped viruses which comprises contacting enveloped viruses with an effective virus inhibiting amount of a phenylketone compound or pharmacologically-acceptable salt thereof, said phenylketone compound corresponding to one of the formulae: ##STR5## wherein R represents hydrogen, halo, or alkoxy of from one to twelve carbon atoms, R' represents hydrogen or halo; R 1 and R 2 represent loweralkyl, or R 1 and R 2 taken together with the nitrogen atom represent a heterocyclic amino group or N-alkyl quaternary heterocyclic ammonium group having four, five or six carbon atoms and zero or one additional ring hetero atom selected from oxygen, sulfur and nitrogen, or R 1 and R 2 taken together with the nitrogen represent triloweralkylammonium, with the proviso that, when the phenylketone compound corresponds to formula I, wherein R' is hydrogen and R 1 and R 2 , taken together with the nitrogen atom represent piperidino, R 2 is other than n-butoxy.
Claim 11
Independent Claim
155 words
A method for inhibiting enveloped viruses which comprises contacting enveloped viruses with an effective virus inhibiting amount of a phenylketone compound or pharmacologically-acceptable salt thereof, said phenylketone compound corresponding to one of the formulae: ##STR5## wherein R represents hydrogen, halo, or alkoxy of from one to twelve carbon atoms, R' represents hydrogen or halo; R 1 and R 2 represent loweralkyl, or R 1 and R 2 taken together with the nitrogen atom represent a heterocyclic amino group or N-alkyl quaternary heterocyclic ammonium group having four, five or six carbon atoms and zero or one additional ring hetero atom selected from oxygen, sulfur and nitrogen, or R 1 and R 2 taken together with the nitrogen represent triloweralkylammonium, with the proviso that, when the phenylketone compound corresponds to formula I, wherein R' is hydrogen and R 1 and R 2 , taken together with the nitrogen atom represent piperidino, R 2 is other than n-butoxy.
Claim 12
Dependent Claim
33 words
Method of claim 9 wherein the phenylketone compound is a member of the group consisting of 4-methoxy-3-piperidino propiophenone, 3-phenyl-4-piperidino-2-butanone, 3',4'-dichloro-3-piperidinopropiophenone, 3'-chloro-3-piperidinopropiophenone, 4'-ethoxy-3-piperidinopropiophenone, 4'-propoxy-3-piperidinopropiophenone, 4'-isobutoxy-3-piperidinopropiophenone, 4'-hexyloxy-3-piperidinopropiophenone, 4'-n-octyloxy-3-piperidinopropiophenone, 4'-n-decyloxy-3-piperidinopropiophenone, 4'-butoxy-3-diethylaminopropiophenone, 4-butoxy-3-morpholinopropiophenone, and 1-[2-(4-butoxybenzoyl)-ethyl]-1-methyl piperidinium iodide.
Claim 13
Dependent Claim
11 words
Method of claim 9 wherein the virus is a herpes virus.
Claim 14
Dependent Claim
8 words
Method of claim 9 wherein R is n-decyloxy.
Claim 15
Dependent Claim
10 words
Method of claim 12 wherein the compound is 4'-n-decyloxy-3-piperidinopropiophenone hydrochloride.
Claim 16
Independent Claim
50 words
A method for alleviating mammalian genital infections of herpes simplex virus type 2 which comprises contacting the genital mucoid cutaneous tissue of a mammal infected with said virus with an effective virus inhibiting amount of a compound selected from the group consisting of dyclonine and a pharmacologically acceptable salt thereof.
Claim 17
Independent Claim
50 words
A method for alleviating mammalian genital infections of herpes simplex virus type 2 which comprises contacting the genital mucoid cutaneous tissue of a mammal infected with said virus with an effective virus inhibiting amount of a compound selected from the group consisting of dyclonine and a pharmacologically acceptable salt thereof.
Claim 18
Dependent Claim
43 words
Method of claim 14 wherein the contacting is carried out by topically applying an effective virus inhibiting amount of said compound to herpes simplex virus type 2 infected genital mucoid cutaneous tissue, and repeating said topical application daily for at least three days.
Claim 19
Dependent Claim
24 words
Method of claim 15 wherein the compound is applied daily at a rate of from about three to about fifteen repeated applications per day.
Claim 20
Dependent Claim
24 words
Method of claim 14 wherein the contacting is carried out by topically applying the compound to intact mammalian genital tissue contaminated with said virus.
Claim 21
Dependent Claim
10 words
Method of claim 14 wherein the mammal is a male.
Claim 22
Dependent Claim
15 words
Method of claim 14 wherein the compound is applied to infected vulvular mucoid cutaneous tissue.
Claim 23
Dependent Claim
28 words
The method of claim 14 wherein the contacting is carried out by topically applying the compound to said tissues of said infected animal in the absence of lesions.
Claim 24
Dependent Claim
10 words
The method of claim 20 wherein the infection is asymptomatic.
Claim 25
Dependent Claim
26 words
Method of claim 14 wherein the compound is applied in the form of a composition containing about 2 percent of said compound in a pharmaceutical carrier.
Claim 26
Dependent Claim
61 words
A prophylactic method useful for inhibiting infection of mammals by enveloped viruses, which comprises topically applying an effective virus-inhibiting amount of a compound selected from the group consisting of dyclonine or a pharmaceutically-acceptable salt thereof to an uninfected mammal contaminated with said virus, in a manner effective to contact contaminating viruses on the cutaneous tissue of said mammal with said compound.
Claim 27
Dependent Claim
61 words
A prophylactic method useful for inhibiting infection of mammals by enveloped viruses, which comprises topically applying an effective virus-inhibiting amount of a compound selected from the group consisting of dyclonine or a pharmaceutically-acceptable salt thereof to an uninfected mammal contaminated with said virus, in a manner effective to contact contaminating viruses on the cutaneous tissue of said mammal with said compound.
Claim 28
Dependent Claim
19 words
Method of claim 23 wherein the compound is topically applied in an amount insufficient to produce significant local anesthesia.
Claim 29
Dependent Claim
16 words
Method of claim 23 wherein the compound is applied to cutaneous tissue contaminated with herpes virus.
Claim 30
Independent Claim
49 words
A method for inactivating herpes simplex virus type 2 which comprises contacting a herpes simplex virus type 2 with an effective virus inhibiting amount of composition containing about 2 percent of a compound selected from the group consisting of dyclonine and a pharmacologically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
Claim 31
Independent Claim
49 words
A method for inactivating herpes simplex virus type 2 which comprises contacting a herpes simplex virus type 2 with an effective virus inhibiting amount of composition containing about 2 percent of a compound selected from the group consisting of dyclonine and a pharmacologically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-06-07 | 1985-12-07 | 1986-06-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-06-07 | 1989-12-07 | 1990-06-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-06-07 | 1993-12-07 | 1994-06-08 | $7700.00 | Window Closed / Lapsed |